Income Statement Balance Sheet Cash Flow Segments

Guardant Health Business Segments

Business, geographic, and product segment breakdowns

Guardant Health generates $1.1B in annual revenue across 4 key segments: Biopharma and data ($217.7M), Licensing and other ($8.8M), Oncology ($738.0M), and Screening ($115.6M). The company-wide operating margin is -41.43%. Based on the Q1 2026 filing.

Biopharma and data (TTM)$217.7M Licensing and other (TTM)$8.8M Oncology (TTM)$738.0M Screening (TTM)$115.6M

Latest FilingQ1 2026

Report Date2026-05-07

Market Cap$17.4B

ROE200.62%

Products & Services

Total Revenue

Segment	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Oncology	$145.6M	$150.6M	$158.7M	$184.4M	$189.9M	$205M
Biopharma and data	$49.5M	$45.4M	$56M	$54.7M	$54M	$53M
Screening	$4.1M	$5.7M	$14.8M	$24.1M	$35.1M	$41.6M
Licensing and other	$2.6M	$1.9M	$2.6M	$2M	$2.2M	$2.1M

Geographic

Revenue

Segment	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
United States	$191.6M	$193.6M	$216.7M	$249.4M	$263.5M	$284.6M
International	$10.2M	$9.9M	$15.4M	$15.8M	$17.7M	$17M

Business Segments

Metric	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Revenue	$201.8M	$203.5M	$232.1M	$265.2M	$281.3M	$301.7M
Sales and marketing expense	$95.8M	$94.1M	$107.8M	$115.9M	$130.5M	$154.4M
Net loss	-$111M	-$95.2M	-$99.9M	-$92.7M	-$128.5M	-$112.1M
Cost of revenue	—	$72.2M	$78.3M	$90.9M	—	$101.6M
Research and development expense	$81.1M	$74.9M	$72.5M	$75.8M	$85.9M	$76.6M
Other segment items	$22.7M	$26.9M	$38.4M	$38.2M	$53.9M	$44.1M
General and administrative expense	$37.8M	$30.6M	$34.9M	$37.1M	$43.5M	$37M
Cost of precision oncology testing	$69.9M	$84.3M	$84.3M	$84.3M	$84.3M	—